Andrea Maier calls for registries, human ITP trials and global standards as healthy longevity medicine races into the clinic.
Singapore is trying to do something difficult: professionalize a field that has expanded far faster than its evidence base. It’s positioning itself as a clinical testbed, moving beyond the ‘anti-aging’ marketplace toward a version of longevity that actually stands up to scrutiny. At the Healthy Longevity Medicine Conference today, Professor Andrea Maier laid out the reality: longevity medicine is already in the clinic, but the scientific scaffolding is still very much under construction. With demand through the roof and commercial models popping up on every corner, we’ve reached a fork in the road. The question isn’t whether longevity clinics are here to stay – they are – but whether they’ll evolve into a rigorous, data-driven discipline or remain a patchwork of ambitious protocols and unfulfilled promise.
Longevity.Technology: Healthy longevity medicine is discovering, in real time, that aspiration scales faster than evidence; the clinics are open, the consumer appetite is unmistakable, yet the discipline itself remains epistemologically fragile. Maier’s intervention isn’t a critique so much as a reality check. If longevity medicine wants to be taken seriously as a medical discipline – rather than just an upscale wellness vertical – it has to stop avoiding the unglamorous machinery of registries, predefined endpoints and randomized allocation. The irony is thick: geroscience has spent decades proving that aging is the upstream driver of all chronic disease, yet when it comes to human trials, the field still looks like a collection of enthusiastic kitchens without a shared recipe book. Embedding trials within registries might not sound revolutionary, but it’s exactly this kind of ‘infrastructure first’ thinking – harmonized data and regulatory literacy – that separates a fleeting movement from a permanent medical specialty. If 55% of a population say they would walk into a longevity clinic tomorrow, the question is no longer whether demand exists; it is whether the field is prepared to deserve it.
A demand surge without a map
Maier’s concern is not theoretical. Data from the Singapore-based HELO Consortium – established to understand what consumers and future clinicians expect from longevity medicine – suggest that public appetite is already substantial. While most respondents were familiar with the concept of lifespan, very few understood healthspan; nevertheless, 55% of the Singapore population indicated that they would attend a longevity clinic.
The motivations were not primarily cosmetic. “Singaporeans have aspiration,” Maier said. “They want to learn new things – which is great, it helps our field.” The dominant ambition, however, was functional rather than aesthetic. “What Singaporeans really want is to live healthier for longer.” When asked about repurposed drugs, roughly one third were receptive – particularly those who expressed confidence in the responsible translation of new gerotherapeutics and were less concerned about side effects.
Yet that enthusiasm collides with what Maier describes as structural disorder. “We have this heterogeneity of the longevity clinic. So where should these 55% of the Singapore population go to? I don’t know.” In the absence of public infrastructure to guide patients toward academically rigorous providers, choice becomes a proxy for quality – and that, she suggests, is a fragile foundation for a medical field.
Standards are not enough
Some jurisdictions have begun to act. Abu Dhabi’s Department of Health has worked with the Healthy Longevity Medicine Society to develop standards for clinical practice – an early attempt to introduce coherence into an emerging sector. Others are watching closely.
But for Maier, standards alone cannot resolve the deeper epistemic problem. “With standards, can we actually say what to do, what not to do? I don’t think so.” Codifying practice is not the same as demonstrating efficacy; nor does it automatically generate safety data across diverse populations. Without shared datasets and agreed endpoints, regulation risks becoming procedural rather than scientific.
The field, in her view, requires infrastructure – not merely guidance.
Registries as public health architecture
Her first pillar is the creation of a precision geromedicine registry in Singapore – a prospective, systematic collection of real-world data on individuals exposed to longevity interventions. Registries are not novel; the first were established in the nineteenth century to track infectious disease, and modern health systems routinely maintain disease-specific registries for cancer, hip fracture and heart failure.
The distinction lies in application. Longevity medicine, positioned upstream of overt pathology, has yet to build comparable surveillance. “We need the real-world evidence: does it actually work?” Maier said. Properly constructed registries – with high participation and standardized data capture – have been associated in other specialties with improved adherence to evidence-based care, reduced mortality and better process metrics.
Her approach is pragmatic: establish a mandatory core dataset across all clinics, prioritize safety monitoring – which has been surprisingly absent from the conversation – and finally bridge the gap between biological age metrics and actual clinical outcomes. Even a baseline level of harmonization would do more than just satisfy regulators; it would create a clear line of sight between the rigorous providers and the opportunistic operators.
Registries are not designed to establish causality; observational data carry inherent limitations. But they offer speed, scale and external validity – and, crucially, the capacity to detect rare adverse events within one to two years rather than a decade.
From mice to humans
The second pillar borrows from geroscience’s own history. The US National Institute on Aging’s Interventions Testing Program was created after repeated failures to reproduce promising murine results across laboratories; by centralizing protocols, randomization and oversight, the program imposed discipline on preclinical longevity research.
“Metformin works, metformin doesn’t work; rapamycin works, rapamycin doesn’t,” Maier said, recalling the field’s earlier inconsistency. Larger, multicenter randomized studies in mice helped stabilize the evidence base. “The ITP program set up via the NIA in America was actually very successful. It’s centralised. There is a committee, there is a steering committee. It’s grown up. I would say the longevity medicine clinics for mice is grown up.”
Her question is whether a human analogue is now required. A Singapore-based human Intervention Testing Program – governed by harmonized SOPs, predefined outcome measures and centralized oversight – could provide a structured platform for evaluating candidate gerotherapeutics in people rather than rodents. Sex- and age-specific endpoints would be specified in advance; data would be collected prospectively, not retrofitted after the fact.
Randomized controlled trials remain indispensable – “very high causality,” as she put it – but they are slow, expensive and typically enroll healthier, motivated participants. Rare event detection is limited when sample sizes are measured in the hundreds.
Hence the third pillar.
Embedding causality in the real world
The model Maier advocates – registry-embedded randomized controlled trials, sometimes termed RRCTs – seeks to combine the internal validity of randomization with the scale and external validity of real-world data capture. The concept is established in cardiology, where large registries created in the early 2000s later served as platforms for embedded trials published in major journals.
“It’s not new,” she said. “You’re embedding the randomised control trials in the registries.”
Under her proposal, every patient attending a participating longevity clinic would enter the registry at first visit. When a physician makes a treatment decision within predefined parameters, that decision could trigger randomization within the registry framework. Outcomes – clinically meaningful and economically relevant – would be specified in advance. Follow-up would be integrated into routine care.
The attraction is structural efficiency. Costs fall because infrastructure already exists; recruitment accelerates because patients are already enrolled; rare adverse events become visible; regulatory acceptance increases as data accumulate. Causality improves without sacrificing real-world relevance.
For a discipline attempting to define itself while under commercial pressure, the appeal is obvious.
A field choosing its future
Longevity medicine is no longer a hypothetical; the clinics are open, patients are asking the right questions and governments are finally starting to pay attention. The architecture we build today – the datasets, the endpoints and the governance – will determine the entire trajectory of the field. It’s the difference between maturing into a coherent clinical specialty or fragmenting into a collection of competing boutique models that never quite reach their potential.
In Singapore, at least, the wager is that infrastructure can keep pace with ambition.
